Incannex Healthcare Limited

Incannex Healthcare Limited engages in the research development and sale of medicinal cannabinoid products in Australia It offers pharmaceutical grade cannabinoid products under the Incannex brand name The companys products include IHL42X which is in Phase II clinical trials for obstructive sleep apnea IHL216A for traumatic brain injury and IHL675A a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions such as acute respiratory distress syndrome chronic obstructive pulmonary disease asthma and bronchitis as well as rheumatoid arthritis and inflammatory bowel diseases It has partnership with The Alfred Hospital and Novotech on IHL42X clinical program for obstructive sleep apnea and Monash Trauma Group at the Department of Neuroscience Monash University to conduct a study on the protective effect of IHL216A in sports concussion The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020 Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney Australia